Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits bacterial RNA synthesis
|
| gptkbp:approves |
gptkb:2011
|
| gptkbp:brand |
gptkb:Xifaxan
|
| gptkbp:category |
B
low risk |
| gptkbp:class |
gptkb:drug
rifamycin derivative |
| gptkbp:clinical_trial |
Phase III trials
|
| gptkbp:contraindication |
hypersensitivity to rifaximin
|
| gptkbp:dosage_form |
500 mg tablet
|
| gptkbp:effective_date |
2011-05-23
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xifaxan
|
| gptkbp:ingredients |
gptkb:rifaximin
|
| gptkbp:interacts_with |
may interact with anticoagulants
may interact with antiepileptics may interact with other antibiotics |
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_used_for |
treatment of traveler's diarrhea
treatment of irritable bowel syndrome with diarrhea treatment of hepatic encephalopathy |
| gptkbp:lifespan |
approximately 6 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Salix_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:price |
varies by pharmacy
|
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:scholarships |
take with or without food
consult doctor if symptoms persist complete full course of therapy do not use for viral infections |
| gptkbp:side_effect |
headache
nausea abdominal pain flatulence |
| gptkbp:storage |
store at room temperature
keep away from moisture |
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
gptkb:rifaximin |
| gptkbp:bfsLayer |
6
|